BOSTON, May 1, 2018 /PRNewswire/ -- Juniper
Pharmaceuticals (Nasdaq:JNP) ("Juniper" or the "Company"), will
hold a conference call on May 10,
2018, to discuss the financial results for the first quarter
ended March 31, 2018, as follows:
|
Date:
|
May 10,
2018
|
|
|
|
Time:
|
8:30 a.m.
EST
|
|
|
|
Dial-in
numbers:
|
Toll free:
(1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or
|
|
|
|
International:
(1-412-902-4218)
|
Audio webcast (live & archive): www.juniperpharma.com, under
'Investors' or click here.
The teleconference replay will be available approximately one
hour after completion through Thursday,
March 15, 2018, at 1-877-344-7529 (U.S.), 1-855-669-9658
(Canada) or 1-412-317-0088
(International). The replay access code is 10119657.
The archived webcast will be available for one year via the
aforementioned URLs.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc.'s core businesses include its
CRINONE® (progesterone gel) franchise and Juniper Pharma Services,
which provides high-end fee-for-service pharmaceutical development
and clinical trials manufacturing to clients. Please visit
www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper
Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt,
Germany, outside the U.S. and of
Allergan plc in the U.S.
Investor Contact:
Laura Perry or Heather
Savelle
Argot Partners
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
To receive Juniper's press releases, SEC filings or calendar
alerts by email click here.
Follow us on LinkedIn
View original content with
multimedia:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-first-quarter-2018-results-on-may-10-2018-300639511.html
SOURCE Juniper Pharmaceuticals, Inc.
